NCT01135511 - A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease | Biotech Hunter

Enrollment

285

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Dry Eye Syndromes

Interventions

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, low dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops

Ophthalmic topical solution, high dose, dosed once/day, 8 weeks

DRUG

CP-690,550 Eye drops-vehicle

Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks

DRUG

Sodium Hyaluronate

Ophthalmic topical solution, dosed 6 times/day, 8 weeks

Trial Locations (28)

Unknown

Pfizer Investigational Site, Ichinomiya

Pfizer Investigational Site, Narashino

Pfizer Investigational Site, Urayasu

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Tokyo

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Fuji

Pfizer Investigational Site, Numazu

Pfizer Investigational Site, Shizuoka

Pfizer Investigational Site, Susono

Pfizer Investigational Site, Chiyoda-ku

Pfizer Investigational Site, Hamura

Pfizer Investigational Site, Minato-ku

Pfizer Investigational Site, Ohta-ku

Pfizer Investigational Site, Sumida-ku

Pfizer Investigational Site, Tachikawa

Pfizer Investigational Site, Taito-ku

Pfizer Investigational Site, Tokyo